Adenovirus Vaccine Vectors and HIV Acquisition Risk: The View from the Summit
Publication • 2013On September 19th, 2013, the National Institute of Allergy and Infectious Diseases (NIAID) sponsored a daylong mini-summit to discuss the safety of adenovirus vaccine vectors in populations at risk for HIV infection.
A Necessary Transformation
TAGline • 2013Simultaneous, not sequential, evaluations of novel drug regimens needed to speed TB treatment research By Lindsay McKenna An example of a multi-arm multi-stage (MAMS) phase II trial design. At the first interim analysis, novel regimen 2 is considered to lack sufficient benefit compared with the control and is not taken forward to stage 2. At…
Beyond ARVs: Advocacy for Non-AIDS Disease Management
TAGline • 2013by Tim Horn Fact: If we’re going to make headway in preventing and treating non-AIDS-related health complications among people with HIV, which are very much on the rise and a serious risk to disease-free survival, we’re going to need the full-on cooperation of pharmaceutical companies manufacturing and developing drugs for non-HIV diseases. Enter Micardis (telmisartan),…
Treatment Action Group and European AIDS Treatment Group Applaud UNITAID Agreement to Reduce the Cost of GeneXpert Rapid TB Test
Statement / Press • 2012Treatment Action Group (TAG) and the European AIDS Treatment Group (EATG) welcome the announcement that a deal has been reached among PEPFAR, USAID, UNITAID, and the Bill & Melinda Gates Foundation to reduce the price of the GeneXpert MTB/RIF rapid test for tuberculosis (TB).
Retrofitting for Purpose: Treatment Optimization
Pipeline • 2012JULY 2012 By Polly Clayden NOTE: a postscript section at the end of this article includes periodic updates since publication in June 2012. In June 2010, the WHO and UNAIDS launched Treatment 2.0, a strategic approach to the achievement of universal access to antiretroviral therapy (ART) and to making the most of the role of…
The Future of TB in the United States: Going, or Growing?
TAGline • 2012By Erica Lessem This summer, Treatment Action Group (TAG) and its partners in fighting tuberculosis (TB) issued a call for zero TB deaths, zero new TB infections, and zero suffering from TB. Yet the U.S., long a leader in TB elimination efforts, is in jeopardy of losing ground in the struggle to get to zero.…
Hepatitis C Drug Development Goes from Pony Ride to Rocket Launch
Pipeline • 2012December 2012 Update – Cure rates presented at the American Association for the Study of Liver Diseases (AASLD) July 2012 By Tracy Swan and Karyn Kaplan Dedicated to Michael Carden A fabulous, kind, brilliant, and hilarious friend and colleague 1971–2012 Special thanks to Jules Levin Introduction Hepatitis C virus (HCV) infection is curable, although it…
Does Obama’s 2013 Budget Herald the End of PEPFAR?
TAGline • 2012Devastating Funding Proposal Undermines the Global Fight Against AIDS by Coco Jervis A sense of disbelief washed over the global AIDS community last month when President Obama unveiled his fiscal year 2013 budget proposal to cut $563 million from the President’s Emergency Plan for AIDS Relief (PEPFAR) program. Cuts of this magnitude could lead to…
The Tuberculosis Treatment Pipeline
Pipeline • 2012Updates to this chapter can be found in the postscript at the end of this page. Original Report July 2012 By Erica Lessem Introduction Tuberculosis (TB) persists as a global health problem, suffering from both insufficient funding and political will. As a result of poor treatment options and inadequate administration of care, increasingly intractable drug-resistant…
Hepatitis C Treatment Access: Spotlight on Thailand/Asia
Pipeline • 2012July 2012 By Karyn Kaplan According to the Universal Declaration of Human Rights and subsequent treaties, all people have a fundamental right to the highest attainable standard of health, as well as a right to the benefits of scientific progress and its applications. Yet many governments in the global South are unable to even progressively…